At Mecwins, we are excited to share the publication in Scientific Reports (by Nature) of an innovative paper introducing our cutting-edge platform AVAC.
AVAC offers a combination of ultra-sensitivity, wide dynamic range and high-throughput capabilities, making it a groundbreaker for disease diagnostics and biomarker analysis. Developed using digital counting of plasmonic nanoparticles as optical labels, the platform can detect biomarkers at ultra-low levels, and supports multiplexed assays, allowing the simultaneous detection of multiple biomarkers, without compromising sensitivity. With its ability to analyze up to 1000 samples per hour, AVAC promises to revolutionize diagnostics, enabling faster, more accurate results for a wide range of diseases, including cardiovascular conditions and HIV. Moreover, its robust dynamic range, spanning four orders of magnitude, ensures that the technology can easily detect both ultra-low and high concentrations.
Thanks to AVAC, new frontiers offering unique potential in both clinical laboratories and research environments in biomarker-based diagnostics just opened up!
Learn more! https://www.nature.com/articles/s41598-025-88992-4
